EPHA2, EPHA4, and EPHA7 Expression in Triple-Negative Breast Cancer.
EPH
basal-like breast cancer
biomarker
ephrin
targeted therapy
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
01 Feb 2022
01 Feb 2022
Historique:
received:
18
12
2021
revised:
21
01
2022
accepted:
28
01
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
Ongoing research continues to elucidate the complex role of ephrin receptors (EPHs) and their ligands (ephrins) in breast cancer pathogenesis, with their varying expression patterns implied to have an important impact on patients' outcome. The current study aims to investigate the clinical significance of EPHA2, EPHA4, and EPHA7 expression in triple-negative breast cancer (TNBC) cases. EPHA2, EPHA4, and EPHA7 protein expression was assessed immunohistochemically on formalin-fixed and paraffin-embedded (FFPE) TNBC tissue sections from 52 TNBC patients and correlated with key clinicopathologic parameters and patients' survival data (overall survival (OS); disease-free survival (DFS)). EPHA2, EPHA4, and EPHA7 expression was further examined in TNBC cell lines. EPHA2 overexpression was observed in 26 (50%) of the TNBC cases, who exhibited a shorter OS and DFS than their low-expression counterparts, with EPHA2 representing an independent prognostic factor for OS and DFS (
Identifiants
pubmed: 35204461
pii: diagnostics12020366
doi: 10.3390/diagnostics12020366
pmc: PMC8871500
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Neuro Oncol. 2011 Nov;13(11):1163-70
pubmed: 21856686
Nat Rev Drug Discov. 2014 Jan;13(1):39-62
pubmed: 24378802
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
World J Gastroenterol. 2008 Oct 7;14(37):5650-6
pubmed: 18837080
Annu Rev Pharmacol Toxicol. 2015;55:465-87
pubmed: 25292427
Oral Oncol. 2008 Dec;44(12):1110-7
pubmed: 18485799
Ann Surg Oncol. 2015 Mar;22(3):874-82
pubmed: 25527230
Oncogene. 2015 Oct 16;34(42):5309-16
pubmed: 25703331
Mod Pathol. 2010 May;23 Suppl 2:S60-4
pubmed: 20436504
Sci Rep. 2017 Nov 3;7(1):14976
pubmed: 29101386
Oncogene. 2009 Apr 9;28(14):1706-13
pubmed: 19234485
Breast Cancer Res Treat. 2011 Jun;127(2):375-84
pubmed: 20602165
Cancer. 2009 Jun 15;115(12):2684-92
pubmed: 19396818
Ann Oncol. 2015 Aug;26(8):1533-46
pubmed: 25939896
Int J Cancer. 2003 Feb 20;103(5):657-63
pubmed: 12494475
Clin Cancer Res. 2003 Feb;9(2):613-8
pubmed: 12576426
Mol Cancer Ther. 2012 Sep;11(9):2021-32
pubmed: 22807579
Semin Cell Dev Biol. 2012 Feb;23(1):102-8
pubmed: 22040912
Breast Cancer Res Treat. 2013 Jul;140(1):63-71
pubmed: 23828499
Histopathology. 2016 Jan;68(1):70-85
pubmed: 26768030
BMC Clin Pathol. 2014 Feb 04;14(1):8
pubmed: 24495444
Biochem Biophys Res Commun. 2004 Jun 11;318(4):882-92
pubmed: 15147954
Cancer Res. 2010 Feb 1;70(3):1141-53
pubmed: 20086179
Oncol Rep. 2004 Mar;11(3):605-11
pubmed: 14767510
CA Cancer J Clin. 2017 Jul 8;67(4):290-303
pubmed: 28294295
Cytokine Growth Factor Rev. 2004 Dec;15(6):419-33
pubmed: 15561600
Biochem Cell Biol. 2011 Apr;89(2):115-29
pubmed: 21455264
Pathol Oncol Res. 2014 Apr;20(2):277-84
pubmed: 24022400
J Cell Mol Med. 2012 Dec;16(12):2894-909
pubmed: 22862837
Adv Anat Pathol. 2015 Sep;22(5):306-13
pubmed: 26262513
Cold Spring Harb Perspect Biol. 2013 Sep 01;5(9):
pubmed: 24003208
PLoS One. 2008 Aug 20;3(8):e2994
pubmed: 18714348
Nat Rev Cancer. 2010 Mar;10(3):165-80
pubmed: 20179713
Cancer Res. 2016 Apr 1;76(7):1825-36
pubmed: 26833123
Breast Cancer Res. 2008;10(6):217
pubmed: 19144211
PLoS One. 2011;6(9):e24426
pubmed: 21935409
Ann Oncol. 2017 Aug 1;28(8):1700-1712
pubmed: 28838210
Nature. 2005 Jun 23;435(7045):1126-30
pubmed: 15973414
J Clin Pathol. 2007 Oct;60(10):1086-91
pubmed: 17158642
J Pharm Pract. 2012 Jun;25(3):319-23
pubmed: 22551559
Oncogene. 2000 Dec 7;19(52):6043-52
pubmed: 11146556
Adv Cancer Res. 2012;114:1-20
pubmed: 22588054
Clin Cancer Res. 2004 Aug 1;10(15):5145-50
pubmed: 15297418
Cancer Res. 2010 Jan 1;70(1):299-308
pubmed: 20028874
J Clin Invest. 2008 Jan;118(1):64-78
pubmed: 18079969
Oncogene. 2017 Oct 5;36(40):5620-5630
pubmed: 28581527
Oncol Rep. 2008 Jan;19(1):151-6
pubmed: 18097589
Sci Signal. 2017 Dec 05;10(508):
pubmed: 29208682
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
Cancer Lett. 2018 Oct 10;434:160-171
pubmed: 30055288
Cell Adh Migr. 2012 Mar-Apr;6(2):138-47
pubmed: 22568950
Oncogene. 2018 Jul;37(30):4073-4093
pubmed: 29700392
Oncogene. 2005 Nov 24;24(53):7859-68
pubmed: 16103880
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Cancer Res. 2001 Mar 1;61(5):2301-6
pubmed: 11280802
Int J Mol Sci. 2021 Aug 05;22(16):
pubmed: 34445116
N Engl J Med. 2009 Feb 19;360(8):790-800
pubmed: 19228622
Gynecol Oncol. 2004 Aug;94(2):312-9
pubmed: 15297167
Pathol Oncol Res. 2009 Sep;15(3):473-8
pubmed: 19048396
Am J Clin Pathol. 2012 Dec;138(6):770-80
pubmed: 23161709
Clin Cancer Res. 2005 Jan 1;11(1):226-31
pubmed: 15671550
Oncotarget. 2016 Apr 19;7(16):21362-80
pubmed: 26870995
Histopathology. 2013 May;62(6):899-907
pubmed: 23551536
J Clin Oncol. 2008 Jul 1;26(19):3153-8
pubmed: 18490649
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Med Sci Monit. 2011 Sep;17(9):BR257-65
pubmed: 21873938
Pathol Oncol Res. 2010 Jun;16(2):267-76
pubmed: 19949912
Cancer Gene Ther. 2004 Nov;11(11):757-66
pubmed: 15359289